Questions and Discussion

Prior to the post-MSLT2 era, the treatment of a microscopically positive SLN was completion lymph node dissection. It is currently accepted that melanoma-specific survival is equivalent between CLND and surveillance. Simultaneously, a growing body of data supports improved outcomes for patients with node positive disease after receipt of adjuvant immunotherapy. It is imperative that surgeons participate in treatment decisions for their patients with positive SLN, and contribute to the research that is shaping this field. The purpose of this session is to understand the current data and provide guidance on how treat patients with positive SLN.